Beyond Air FCF par action

Que fait Beyond Air ? Beyond Air Inc, trading under the ticker symbol XAIR and identified by ISIN US08862L2025, is a clinical-stage medical device and biopharmaceutical company headquartered in Garden City, New York. The firm officially entered the public markets with an initial public offering on May 7, 2019. Despite its technological focus, the company operates with a lean organizational structure, currently employing 23 full-time staff members. The primary mission of Beyond Air is centered on the development of advanced therapeutic solutions for serious respiratory conditions, leveraging proprietary technology to generate nitric oxide directly from ambient air. This approach distinguishes its platform from traditional methods that require complex storage and handling of compressed gas cylinders. The core of the company's innovation is the Beyond Air Nitric Oxide Generator and Delivery System, known as the NOGDS. This device is engineered to produce nitric oxide on-site from the surrounding air and deliver it in precise dosages directly to the lungs. By generating the gas in real-time, the system aims to provide a safer and more convenient method of administration for patients requiring nitric oxide therapy. The technology is designed to deliver high concentrations of nitric oxide, which is critical for treating specific pulmonary vascular and inflammatory conditions. The company has tailored its product portfolio to address distinct clinical needs, resulting in specialized iterations of its platform. These include Beyond Air-PH, Beyond Air-BRO, and Beyond Air-NTM, each targeting a specific medical indication. The therapeutic focus of Beyond Air spans several challenging respiratory diseases. One key area of development is persistent pulmonary hypertension of the newborn, a serious condition affecting infants where blood flow to the lungs is restricted. Another significant focus is bronchiolitis, a common viral infection that causes inflammation in the small airways of the lungs, particularly in young children. The company is also investigating applications for nontuberculous mycobacteria infections, which can cause chronic lung disease in susceptible individuals. By utilizing its unique gas generation technology, Beyond Air aims to improve patient outcomes in these areas by providing consistent and controlled delivery of nitric oxide. The company's website, http://www.ait-pharm.com, serves as a resource for further information regarding its clinical progress and technological developments. As a player in the health care sector, Beyond Air continues to advance its pipeline through clinical evaluation and strategic development, seeking to establish its NOGDS technology as a standard in respiratory care. Beyond Air est l'une des entreprises les plus populaires sur Eulerpool.